

PROF. RONIT SATCHI-FAINARO

Ronit Satchi-Fainaro is a full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of Tel Aviv University Cancer Biology Research Center, Director of the TAU Kahn 3D BioPrinting Initiative, and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd. and the Board of Governors of Tel Aviv University, and is a member of the Scientific Advisory Board (SAB) of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the University of Lisbon, the Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), The Rothschild and Fulbright Fellowships Committees, several VCs, and editorial boards of scientific journals.

Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of highly selective targeting molecules integrating biology, chemistry, medicine, data science, engineering and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She has published more than 150 manuscripts, 13 book chapters, edited two books, is named inventor on 60 patents, some of which were licensed to Pharmaceutical and Biotech companies, and has delivered over 500 lectures worldwide. She founded three spin-off companies and is actively engaged in translational research with several industry partners and in science outreach.